S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
BREAKING: Tiny biotech successfully treats blindness (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
BREAKING: Tiny biotech successfully treats blindness (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
BREAKING: Tiny biotech successfully treats blindness (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
BREAKING: Tiny biotech successfully treats blindness (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
BREAKING: Tiny biotech successfully treats blindness (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
BREAKING: Tiny biotech successfully treats blindness (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
BREAKING: Tiny biotech successfully treats blindness (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
BREAKING: Tiny biotech successfully treats blindness (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
BREAKING: Tiny biotech successfully treats blindness (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
BREAKING: Tiny biotech successfully treats blindness (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
BREAKING: Tiny biotech successfully treats blindness (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
BREAKING: Tiny biotech successfully treats blindness (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
NASDAQ:CBPO

China Biologic Products (CBPO) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$118.24
$120.05
50-Day Range
$117.88
$119.99
52-Week Range
$99.74
$120.05
Volume
24,016 shs
Average Volume
148,695 shs
Market Capitalization
$4.72 billion
P/E Ratio
33.52
Dividend Yield
N/A
Price Target
N/A

CBPO stock logo

About China Biologic Products (NASDAQ:CBPO) Stock

China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, auto-immune deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.


CBPO Stock News Headlines

Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Blood Money -- This Plasma Maker Is Set to Soar
See More Headlines
Receive CBPO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for China Biologic Products and its competitors with MarketBeat's FREE daily newsletter.

CBPO Company Calendar

Last Earnings
3/28/2021
Today
10/03/2023

Industry, Sector and Symbol

Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CBPO
Fax
N/A
Employees
2,269
Year Founded
1989

Profitability

Net Income
$138.81 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$503.70 million
Cash Flow
$5.01 per share
Book Value
$45.09 per share

Miscellaneous

Free Float
N/A
Market Cap
$4.72 billion
Optionable
Optionable
Beta
0.47

Social Links

The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Joseph Chow (Age 59)
    Chairman & CEO
  • Mr. Ming Yang (Age 49)
    Chief Financial Officer
  • Mr. Ming Yin (Age 43)
    Sr. VP













CBPO Stock - Frequently Asked Questions

How were China Biologic Products' earnings last quarter?

China Biologic Products Holdings, Inc. (NASDAQ:CBPO) posted its quarterly earnings results on Sunday, March, 28th. The biopharmaceutical company reported $0.91 EPS for the quarter, topping analysts' consensus estimates of $0.69 by $0.22. The biopharmaceutical company earned $112.10 million during the quarter. China Biologic Products had a trailing twelve-month return on equity of 8.32% and a net margin of 27.43%.

What other stocks do shareholders of China Biologic Products own?

Based on aggregate information from My MarketBeat watchlists, some companies that other China Biologic Products investors own include Lexicon Pharmaceuticals (LXRX), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD) and Amgen (AMGN).

What is China Biologic Products' stock symbol?

China Biologic Products trades on the NASDAQ under the ticker symbol "CBPO."

What is China Biologic Products' stock price today?

One share of CBPO stock can currently be purchased for approximately $119.99.

How much money does China Biologic Products make?

China Biologic Products (NASDAQ:CBPO) has a market capitalization of $4.72 billion and generates $503.70 million in revenue each year. The biopharmaceutical company earns $138.81 million in net income (profit) each year or $4.28 on an earnings per share basis.

How many employees does China Biologic Products have?

The company employs 2,269 workers across the globe.

How can I contact China Biologic Products?

China Biologic Products' mailing address is 18TH FL JIALONG INTERNATIONALBUILDING 19 CHAOYANG PARK ROAD CHAOYANG DISTRICT, BEIJING F4, 100125. The official website for the company is www.chinabiologic.com. The biopharmaceutical company can be reached via phone at 861065983111 or via email at ir@chinabiologic.com.

This page (NASDAQ:CBPO) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -